

Almirall appoints Karin Louise Dorrepaal as new independent board member

- **Karin Louise Dorrepaal is the first woman to join Almirall's Board of Directors, which is made up of ten members**
- **Dorrepaal, who is Dutch, has a PH.D. in Medicine as well as a MBA together with an extensive international experience in the pharmaceutical sector and in consultancy.**

Barcelona, 19 November 2012.- Karin Louise Dorrepaal has been appointed, by co-option, independent board member of Almirall, whose Board of Directors comprises ten members. The appointment will take effect as of 1 January and will be ratified in Almirall's next Annual General Meeting.

Dorrepaal, from Holland, has a PH.D. in Medicine as well as a MBA together with an extensive professional career spanning over 25 years during which she has held top level positions in the pharmaceutical sector and the international strategic consultancy area.

Karin Louise Dorrepaal has led various pharmaceutical business model transformation processes and currently holds non-executive positions in companies related to the healthcare sector and consultancy. Her experience, her business acumen and her global insight validate her appointment.

Almirall

Almirall is a pharmaceutical company committed to innovate through valuable medicines. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing now and to future generations. Almirall medicines, focused on respiratory, dermatology, gastrointestinal and pain, are currently in over 70 countries while the company has direct presence in Europe, Mexico and Canada through 13 affiliates.

For more information, visit: www.almirall.com

More information:

Ketchum

Sonia San Segundo

sonia.sansegundo@ketchum.com

Tel.: 00 34 91 788 32 00

Investor Relations Contact

Almirall

Jordi Molina

jordi.molina@almirall.com

Tel.: 00 34 93 291 30 87